News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
15.01.2020 13:00:00

Better Buy: Johnson & Johnson vs. Merck

Johnson & Johnson (NYSE: JNJ) and Merck & Co. (NYSE: MRK) are two heavyweights in the pharmaceutical sector. Both companies generate billions in sales and profits and have developed many successful drugs over the years.However, both underperformed in 2019. Merck's 19% return last year was well above the 13% that Johnson & Johnson produced for its investors, but shares of both companies still fell well shy of the 30% return enjoyed by the S&P 500.Deciding which stock is the better buy today is no easy task. Both offer investors some great opportunities in healthcare, and there's not a whole lot separating the two. Let's take a closer look at the two stocks to see which one has the edge today.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Merck Co.mehr Analysen

07.01.20 Merck Sector Perform RBC Capital Markets
29.10.19 Merck Neutral Goldman Sachs Group Inc.
30.09.19 Merck Neutral JP Morgan Chase & Co.
25.01.19 Merck Market Perform BMO Capital Markets
25.10.18 Merck Conviction Buy List Goldman Sachs Group Inc.

Eintrag hinzufügen

SMI mit neuem Hoch – UBS mit neuem Chef | BX Swiss TV

Aktien in diesem Artikel

Merck KGaA 102.20 -1.02% Merck KGaA
Merck Co. 82.51 0.88% Merck Co.

Finanzen.net News